Corporate Report

Overview

The report describes Fuji Pharma's record FY2023 consolidated sales, formal sustainability governance and materiality process, and expanded climate disclosures under TCFD recommendations. It reports Scope 1, Scope 2, and Scope 3 emissions, targets carbon neutrality by 2050, and is shifting Toyama Plant electricity toward renewable energy. The report also highlights human-capital initiatives, women's advancement measures, and the Group's health-focused business model.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 October 2022 – 30 September 2023
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services